Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.

MLA

Shah, Arpeet T., et al. “Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.” Clinical Lung Cancer, vol. 25, no. 6, Sept. 2024, pp. 550–59. EBSCOhost, https://doi.org/10.1016/j.cllc.2024.06.006.

APA

Shah, A. T., Blanchard, I., Padda, S. K., Wakelee, H. A., & Neal, J. W. (2024). Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer. Clinical Lung Cancer, 25(6), 550–559. https://doi.org/10.1016/j.cllc.2024.06.006

Chicago

Shah, Arpeet T, Isabelle Blanchard, Sukhmani K Padda, Heather A Wakelee, and Joel W Neal. 2024. “Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.” Clinical Lung Cancer 25 (6): 550–59. doi:10.1016/j.cllc.2024.06.006.